Determining When to Stop Prostate Specific Antigen Monitoring after Radical Prostatectomy

the Role of Ultrasensitive Prostate Specific Antigen

Kazuhiro Matsumoto, Akari Komatsuda, Yoshinori Yanai, Naoya Niwa, Takeo Kosaka, Ryuichi Mizuno, Eiji Kikuchi, Akira Miyajima, Mototsugu Oya

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose We analyzed long-term followup data after radical prostatectomy to determine how long we should follow patients in whom the serum prostate specific antigen level measured by an ultrasensitive assay was consistently low. Materials and Methods We retrospectively reviewed clinicopathological data for 582 consecutive patients who underwent open or laparoscopic radical prostatectomy between 1995 and 2004, excluding 4 patients who received adjuvant therapy. We stratified the patients according to prostate specific antigen at 3 and 5 years after surgery, and examined subsequent biochemical recurrence (elevation of prostate specific antigen to greater than 0.2 ng/ml) during followup. Mean followup was 9.7 years. Results At 3 years after surgery prostate specific antigen levels were measured by an ultrasensitive assay in 323 patients who had not experienced biochemical recurrence. In 187 patients with undetectable prostate specific antigen levels (less than 0.01 ng/ml) the 10 and 15-year biochemical recurrence-free survival rates were 99% and 96%, respectively. At 5 years after surgery prostate specific antigen was measured in 315 patients by the ultrasensitive assay. In 162 patients with undetectable prostate specific antigen levels the 10 and 15-year biochemical recurrence-free survival rates were both 100%. In this group the prostate specific antigen level at last followup was less than 0.01 ng/ml in 132 patients, 0.01 to 0.03 ng/ml in 27 patients, and 0.06 ng/ml, 0.07 ng/ml and 0.11 ng/ml in 1 patient each. Conclusions This long-term review indicates that if patients have continuously undetectable prostate specific antigen levels by an ultrasensitive assay for 5 years, prostate specific antigen monitoring can be stopped with an extremely low risk of subsequent biochemical recurrence.

Original languageEnglish
Pages (from-to)655-661
Number of pages7
JournalJournal of Urology
Volume197
Issue number3
DOIs
Publication statusPublished - 2017 Mar 1

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Recurrence
Survival Rate

Keywords

  • follow-up studies
  • monitoring
  • physiologic
  • prostate-specific antigen
  • prostatectomy
  • recurrence

ASJC Scopus subject areas

  • Urology

Cite this

Determining When to Stop Prostate Specific Antigen Monitoring after Radical Prostatectomy : the Role of Ultrasensitive Prostate Specific Antigen. / Matsumoto, Kazuhiro; Komatsuda, Akari; Yanai, Yoshinori; Niwa, Naoya; Kosaka, Takeo; Mizuno, Ryuichi; Kikuchi, Eiji; Miyajima, Akira; Oya, Mototsugu.

In: Journal of Urology, Vol. 197, No. 3, 01.03.2017, p. 655-661.

Research output: Contribution to journalArticle

@article{3c5af4231af24818af17b9400edefcd3,
title = "Determining When to Stop Prostate Specific Antigen Monitoring after Radical Prostatectomy: the Role of Ultrasensitive Prostate Specific Antigen",
abstract = "Purpose We analyzed long-term followup data after radical prostatectomy to determine how long we should follow patients in whom the serum prostate specific antigen level measured by an ultrasensitive assay was consistently low. Materials and Methods We retrospectively reviewed clinicopathological data for 582 consecutive patients who underwent open or laparoscopic radical prostatectomy between 1995 and 2004, excluding 4 patients who received adjuvant therapy. We stratified the patients according to prostate specific antigen at 3 and 5 years after surgery, and examined subsequent biochemical recurrence (elevation of prostate specific antigen to greater than 0.2 ng/ml) during followup. Mean followup was 9.7 years. Results At 3 years after surgery prostate specific antigen levels were measured by an ultrasensitive assay in 323 patients who had not experienced biochemical recurrence. In 187 patients with undetectable prostate specific antigen levels (less than 0.01 ng/ml) the 10 and 15-year biochemical recurrence-free survival rates were 99{\%} and 96{\%}, respectively. At 5 years after surgery prostate specific antigen was measured in 315 patients by the ultrasensitive assay. In 162 patients with undetectable prostate specific antigen levels the 10 and 15-year biochemical recurrence-free survival rates were both 100{\%}. In this group the prostate specific antigen level at last followup was less than 0.01 ng/ml in 132 patients, 0.01 to 0.03 ng/ml in 27 patients, and 0.06 ng/ml, 0.07 ng/ml and 0.11 ng/ml in 1 patient each. Conclusions This long-term review indicates that if patients have continuously undetectable prostate specific antigen levels by an ultrasensitive assay for 5 years, prostate specific antigen monitoring can be stopped with an extremely low risk of subsequent biochemical recurrence.",
keywords = "follow-up studies, monitoring, physiologic, prostate-specific antigen, prostatectomy, recurrence",
author = "Kazuhiro Matsumoto and Akari Komatsuda and Yoshinori Yanai and Naoya Niwa and Takeo Kosaka and Ryuichi Mizuno and Eiji Kikuchi and Akira Miyajima and Mototsugu Oya",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.juro.2016.08.098",
language = "English",
volume = "197",
pages = "655--661",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Determining When to Stop Prostate Specific Antigen Monitoring after Radical Prostatectomy

T2 - the Role of Ultrasensitive Prostate Specific Antigen

AU - Matsumoto, Kazuhiro

AU - Komatsuda, Akari

AU - Yanai, Yoshinori

AU - Niwa, Naoya

AU - Kosaka, Takeo

AU - Mizuno, Ryuichi

AU - Kikuchi, Eiji

AU - Miyajima, Akira

AU - Oya, Mototsugu

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Purpose We analyzed long-term followup data after radical prostatectomy to determine how long we should follow patients in whom the serum prostate specific antigen level measured by an ultrasensitive assay was consistently low. Materials and Methods We retrospectively reviewed clinicopathological data for 582 consecutive patients who underwent open or laparoscopic radical prostatectomy between 1995 and 2004, excluding 4 patients who received adjuvant therapy. We stratified the patients according to prostate specific antigen at 3 and 5 years after surgery, and examined subsequent biochemical recurrence (elevation of prostate specific antigen to greater than 0.2 ng/ml) during followup. Mean followup was 9.7 years. Results At 3 years after surgery prostate specific antigen levels were measured by an ultrasensitive assay in 323 patients who had not experienced biochemical recurrence. In 187 patients with undetectable prostate specific antigen levels (less than 0.01 ng/ml) the 10 and 15-year biochemical recurrence-free survival rates were 99% and 96%, respectively. At 5 years after surgery prostate specific antigen was measured in 315 patients by the ultrasensitive assay. In 162 patients with undetectable prostate specific antigen levels the 10 and 15-year biochemical recurrence-free survival rates were both 100%. In this group the prostate specific antigen level at last followup was less than 0.01 ng/ml in 132 patients, 0.01 to 0.03 ng/ml in 27 patients, and 0.06 ng/ml, 0.07 ng/ml and 0.11 ng/ml in 1 patient each. Conclusions This long-term review indicates that if patients have continuously undetectable prostate specific antigen levels by an ultrasensitive assay for 5 years, prostate specific antigen monitoring can be stopped with an extremely low risk of subsequent biochemical recurrence.

AB - Purpose We analyzed long-term followup data after radical prostatectomy to determine how long we should follow patients in whom the serum prostate specific antigen level measured by an ultrasensitive assay was consistently low. Materials and Methods We retrospectively reviewed clinicopathological data for 582 consecutive patients who underwent open or laparoscopic radical prostatectomy between 1995 and 2004, excluding 4 patients who received adjuvant therapy. We stratified the patients according to prostate specific antigen at 3 and 5 years after surgery, and examined subsequent biochemical recurrence (elevation of prostate specific antigen to greater than 0.2 ng/ml) during followup. Mean followup was 9.7 years. Results At 3 years after surgery prostate specific antigen levels were measured by an ultrasensitive assay in 323 patients who had not experienced biochemical recurrence. In 187 patients with undetectable prostate specific antigen levels (less than 0.01 ng/ml) the 10 and 15-year biochemical recurrence-free survival rates were 99% and 96%, respectively. At 5 years after surgery prostate specific antigen was measured in 315 patients by the ultrasensitive assay. In 162 patients with undetectable prostate specific antigen levels the 10 and 15-year biochemical recurrence-free survival rates were both 100%. In this group the prostate specific antigen level at last followup was less than 0.01 ng/ml in 132 patients, 0.01 to 0.03 ng/ml in 27 patients, and 0.06 ng/ml, 0.07 ng/ml and 0.11 ng/ml in 1 patient each. Conclusions This long-term review indicates that if patients have continuously undetectable prostate specific antigen levels by an ultrasensitive assay for 5 years, prostate specific antigen monitoring can be stopped with an extremely low risk of subsequent biochemical recurrence.

KW - follow-up studies

KW - monitoring

KW - physiologic

KW - prostate-specific antigen

KW - prostatectomy

KW - recurrence

UR - http://www.scopus.com/inward/record.url?scp=85011093204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011093204&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2016.08.098

DO - 10.1016/j.juro.2016.08.098

M3 - Article

VL - 197

SP - 655

EP - 661

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -